Evidence map›Paper›PMID 31243233›Full record

Trial reportInternal medicine (Tokyo, Japan)2019

Phase I/II Study: Experience with the Late Onset of Acute Pancreatitis after the Start of Chemotherapy with Gemcitabine Plus nab-Paclitaxel for Metastatic Pancreatic Cancer.

Makoto Ueno, Fumio Nagashima, Hideki Ueno, Masafumi Ikeda, Shinichi Ohkawa, Nobumasa Mizuno, Tatsuya Ioka, Yasushi Omuro, Takako Eguchi Nakajima, Junji Furuse

Open access · diamondAbstract readCase ReportsClinical Trial, Phase IClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Internal medicine (Tokyo, Japan), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 1 country.

Makoto UenoDivision of Hepatobiliary and Pancreatic Oncology, Kanagawa Cancer Center, Japan.
Fumio NagashimaDepartment of Medical Oncology, Kyorin University Faculty of Medicine, Japan.
Hideki UenoDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Japan.
Masafumi IkedaDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Japan.
Shinichi OhkawaDivision of Hepatobiliary and Pancreatic Oncology, Kanagawa Cancer Center, Japan.
Nobumasa MizunoDepartment of Gastroenterology, Aichi Cancer Center Hospital, Japan.
Tatsuya IokaDepartment of Cancer Survey and Gastrointestinal Oncology, Osaka International Cancer Institute, Japan.
Yasushi OmuroDepartment of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan.
Takako Eguchi NakajimaDepartment of Medical Oncology, St. Marianna University School of Medicine Hospital, Japan.
Junji FuruseDepartment of Medical Oncology, Kyorin University Faculty of Medicine, Japan.
Kanagawa Cancer CenterKyorin University · JPAichi Cancer Center · JPNational Cancer Center Hospital East · JPOsaka Medical Center for Cancer and Cardiovascular Diseases · JPSt. Marianna University School of Medicine · JPTokyo Metropolitan Komagome Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gemcitabine plus nab-paclitaxel is the current standard chemotherapy for patients with metastatic pancreatic cancer. We conducted a phase I/II study in Japan, in which high response rates and manageable toxicity were observed. In this study, two patients were reported as experiencing pancreatitis due to chemotherapy. In general, pancreatitis is sometimes observed when the tumor involves the pancreatic duct, and the onset is observed before the diagnosis or at the initial stage. The onset of pancreatitis in these cases was unique and observed after the start of chemotherapy. Pancreatitis may be induced by the alleviation of stenosis of the pancreatic duct associated with tumor shrinkage.

Indexed as

Acute DiseaseAgedAlbuminsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Pancreatic DuctalDeoxycytidineFemaleGemcitabineHumansMaleMiddle AgedPaclitaxelPancreatic NeoplasmsPancreatitisTomography, X-Ray Computed130-nm albumin-bound paclitaxelAlbuminsDeoxycytidineGemcitabinePaclitaxeladverse eventgemcitabinenab-paclitaxelpancreatic adenocarcinomataxane

Identifiers

PMID31243233
PMCPMC6859393
OpenAlexW2955066056

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.